vVardis Prices $175M IPO as Drill-Free Cavity Treatment Gains Attention

The vVardis IPO was priced at $18 per share on November 13, 2026, raising about $175 million. Shares are expected to start trading on the NYSE the same day under the ticker VVVV. vVardis makes Curodont, a peptide treatment for early tooth decay that requires no drilling or anesthesia.

TL;DR

• vVardis sold 9,722,223 Class A shares at $18, below its marketed $21–$24 range.

• The company expects NYSE trading under VVVV on November 13 and closing near November 16.

• Curodont uses the peptide P11-4 to remineralize early, noncavitated lesions without drilling.

• Six clinical trials show higher caries arrest, and every one carried elevated risk of bias.

vVardis Prices IPO Below Its Initial Range

The final terms came in under what vVardis marketed to investors one week earlier.

According to the company's pricing announcement, vVardis sold 9,722,223 Class A shares at $18.00 each. That equals roughly $175 million before underwriting fees and expenses. The underwriters also hold a 30-day option to buy up to 1,458,333 additional shares.

vVardis launched the deal on November 6 at $21–$24 per share. On November 12, Reuters reported a cut to 8.3 million shares amid a tech selloff. The final deal moved the other way on share count. vVardis sold more shares at a lower price and still landed near $175 million.

Swiss site cash.ch put the implied valuation near $3.28 billion, down from $4.37 billion. Pricing below range usually signals softer investor demand at the original terms. It says nothing yet about how the stock will trade.

The shares are expected to begin trading on the NYSE on November 13, 2026. The offering is expected to close on or about November 16, subject to customary conditions. Goldman Sachs and J.P. Morgan lead the deal as joint bookrunning managers. The F-1 registration statement also shows the founders keeping majority voting control through Class B shares.

What Is vVardis and Its Curodont Technology?

vVardis is a Zug, Switzerland, company built around one product family, Curodont.

Dentist sisters Haley and Goly Abivardi founded vVardis in 2020. Before that, they built and sold the Swiss Smile dental clinic chain.

Curodont contains the self-assembling peptide P11-4. The clinician cleans and conditions the lesion, then brushes on the liquid. The peptide diffuses into the porous subsurface enamel and assembles into a 3D scaffold. That scaffold draws calcium and phosphate from saliva. New hydroxyapatite crystals then form inside the lesion.

The US product is Curodont Repair Fluoride Plus, which adds sodium fluoride. It generates most company revenue and is sold in the US only through Henry Schein. Curodont Repair, the fluoride-free version, is a medical device in the UK and parts of Europe.

A filling replaces tooth structure that decay has already destroyed. Curodont works earlier, on lesions where the enamel surface is still intact.

Can Curodont Treat Cavities Without Drilling?

Curodont can treat a specific group of early lesions without drilling, and that group is narrow.

Good candidates are active, noncavitated lesions, like white spots with an intact surface. Many sit on smooth surfaces, in occlusal fissures, or around orthodontic brackets. Once the surface collapses into a cavity, the peptide has no lesion framework left to rebuild. Those teeth still need restorative treatment.

The strongest summary is a 2023 JADA systematic review and meta-analysis of six trials. Curodont Repair likely raised caries arrest, with a relative risk of 1.82. The number needed to treat was 2.8, and mean lesion size fell by 32%.

The same review listed clear limits. All trials had elevated risk of bias, and two used unmasked assessors. The authors called for longer trials. No included study tested Curodont Repair Fluoride Plus, the version sold in the US.

In the US, that product is regulated as an over-the-counter drug under an FDA monograph. The company's filing states the FDA has not determined its safety or effectiveness.

What the Listing Means for Dental Practices

For practices, the IPO raises practical questions about reach, billing, and evidence.

vVardis says its US product reached over 20,000 dental practices by June 30, 2026. Renaissance Capital puts the US total at about 110,000 general practices. Most offices have yet to place an order.

Billing now has a defined path. Practices can report the procedure with CDT code D2991, which took effect in 2024. Payer coverage still varies, so many offices charge it as fee-for-service. Patients then compare that fee with conventional dental fillings, often $150 to $400 uninsured.

Detection decides the size of the treatable pool. AI caries detection software can flag early enamel lesions that a busy exam might miss. Each flagged lesion then needs a clear decision, whether to monitor, remineralize, or restore.

Each dental treatment plan should record lesion site, ICDAS score, and recall interval. Follow-up radiographs then show whether a lesion arrested or progressed.

The new capital funds US sales growth for a company still losing money. First-half 2026 results showed a $27.8 million net loss on $28.6 million in revenue. A stock listing does not show that Curodont outperforms fluoride varnish or sealants.

Bottom Line

vVardis priced its IPO at $18, raising about $175 million below its marketed range. The company now has public capital to push a drill-free treatment for early caries. Curodont has promising short-term data on noncavitated lesions. Cavitated teeth still need fillings, and longer trials are missing.